Q4 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2025 / 09:30PM GMT

Release Date Price: MXN902.37

Transcript 10-K8-K

Key Points

Positve

Mirum Pharmaceuticals Inc (MIRM) reported total net product sales of $336.4 million for 2024, exceeding the upper end of their revised guidance range.
The company achieved a 43% year-over-year increase in net product sales in the fourth quarter of 2024.
LIVMARLI's net product sales increased by 50% compared to 2023, driven by strong demand in Alagille syndrome and PFIC.
The FDA approved CTEXLI for cerebrotendinous xanthomatosis (CTX) in adults, providing 7 years of market exclusivity.
Mirum Pharmaceuticals Inc (MIRM) is cash flow positive and expects to maintain this status in 2025, with projected net product sales between $420 million and $435 million.

Negative

Total operating expenses for 2024 were $424.5 million, which includes significant R&D and SG&A expenses.
The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements.
The convertibles mature in four years, which could impact future financial planning.
The company is still in the early stages of its journey, indicating potential challenges in achieving long-term strategic goals.
Enrollment for some clinical studies, such as the VANTAGE study, is not expected to complete until 2026, delaying potential market entry.

Operator

Hello, and welcome to Mirum Pharmaceuticals reports fourth quarter and year-end 2024 financial results and provides business update. My name is Elliot, and I'll be your coordinator today. (Operator Instructions)

I would now like to hand over to Andrew McKibben, Senior Vice President of Strategic Finance and Investor Relations. Please go ahead.

Andrew Mckibben

Mirum Pharmaceuticals Inc - IR Contact Officer

Thanks, Elliot, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals fourth-quarter 2024 conference call. I'm joined today by our CEO, Chris Peetz; our Chief Medical Officer, Joanne Quan; and Eric Bjerkholt, our Chief Financial Officer. Peter Radovich, our President and Chief Operating Officer, could not be with us today as he's at an international launch event in Europe this week. Earlier today, Mirum issued a news release announcing the company's results for the fourth quarter and full year 2024.

Copies of this news release and SEC filings can be found in the Investors section of our website. Before we start, I'd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.